TACSTD2 and breast carcinoma: Although in the breast cancer study TROPION-B01 there was no association between Trop2 expression levels and clinical response to Dato-Dxd in patients, our study results demonstrating a correlation between TROP2 expression and preclinical activity are in agreement with previous preclinical work with other ADCs (i.e., SG) targeting TROP2 (43).